Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions.

Serial proton magnetic resonance spectroscopy (MRS), was carried out at 1-2 monthly intervals on eight patients with multiple sclerosis who presented with evidence of a large acute cerebral white matter lesion. An MRS was obtained from acute lesions (volumes of interest 4-12 ml), which at presentation showed gadolinium-diethylenetriamine penta-acetic acid enhancement, and from similar volumes of normal appearing white matter lateral to the lesion and nearer the scalp. Follow-up ranged from 4 to 9 months (mean 6 months). Short echo spectra from acute enhancing lesions invariably showed the presence of large resonances at 0.9 and 1.3 p.p.m. compared with normal appearing white matter and healthy age matched controls, indicating that these peaks were not the result of voxel contamination from scalp fat. These resonances, which probably represent lipid products of myelin breakdown, were detected in lesions which had been enhancing for < 1 month and remained elevated for a mean of 5 months (range 4-8 months). The results provide evidence that short echo proton MRS can detect myelin breakdown products and that myelin breakdown occurs during the initial inflammatory stage of lesion development. The ratio of N-acetylaspartate (NAA) (a neuronal marker) relative to creatine was reduced in acute lesions and in normal appearing white matter. In six of the lesions studied there was, however, a subsequent rise in the NAA/creatine ratio indicating that axonal loss is not the only mechanism of reduction in the NAA/creatine ratio.

[1]  R. Kamman,et al.  In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis. , 1992, Archives of neurology.

[2]  J. Frahm,et al.  Improvements in localized proton NMR spectroscopy of human brain. Water suppression, short echo times, and 1 ml resolution , 1990 .

[3]  William H. Oldendorf,et al.  N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.

[4]  J. Frahm,et al.  Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites , 1989, Magnetic resonance in medicine.

[5]  P E Wright,et al.  Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. , 1986, The Journal of biological chemistry.

[6]  P M Matthews,et al.  Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.

[7]  F. Roncaroli,et al.  Neuropathology of multiple sclerosis , 2012 .

[8]  P A Narayana,et al.  Proton MR spectroscopy of gadolinium‐enhanced multiple sclerosis plaques , 1992, Journal of magnetic resonance imaging : JMRI.

[9]  J. Frahm,et al.  Acute demyelinating disease. Classification and non‐invasive diagnosis , 1992, Acta neurologica Scandinavica.

[10]  J. Cumings,et al.  Biochemistry and the Central Nervous System , 1967, Neurology.

[11]  T Revesz,et al.  Multiple sclerosis. Pathology of recurrent lesions. , 1993, Brain : a journal of neurology.

[12]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[13]  T. Patel,et al.  Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. , 1979, The Biochemical journal.

[14]  P Rudge,et al.  The site of the lesion causing deafness in multiple sclerosis. , 1988, Scandinavian audiology.

[15]  K. Brindle,et al.  The appearance of neutral lipid signals in the 1H NMR spectra of a myeloma cell line correlates with the induced formation of cytoplasmic lipid droplets , 1993, Magnetic resonance in medicine.

[16]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  D. Gadian,et al.  Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis , 1991, The Lancet.

[18]  H. Bruhn,et al.  Multiple sclerosis in children: Cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo , 1992, Annals of neurology.

[19]  D. Paty,et al.  Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.

[20]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[21]  G J Barker,et al.  The proton NMR spectrum in acute EAE: The significance of the change in the Cho:Cr ratio , 1993, Magnetic resonance in medicine.

[22]  Henry McIlwain Biochemistry and the Central Nervous System , 1955 .

[23]  Detection of thymosin beta 4 in situ in a guinea pig cerebral cortex preparation using 1H NMR spectroscopy. , 1992, The Journal of biological chemistry.

[24]  J. Olesen,et al.  In vivo determination of T1 and T2 in the brain of patients with severe but stable multiple sclerosis , 1988, Magnetic resonance in medicine.

[25]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[26]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[27]  A. Thompson,et al.  High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[28]  W. Stehbens Pathology of the cerebral blood vessels , 1972 .

[29]  W. Mcdonald,et al.  The pathological evolution of multiple sclerosis , 1992, Neuropathology and applied neurobiology.

[30]  D. N. Landon,et al.  Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. , 1990, Brain : a journal of neurology.

[31]  P. Jenner Biochemistry and the Central Nervous System (5th Ed.) , 1986 .

[32]  K. Behar,et al.  Assignment of resonances in the 1H spectrum of rat brain by two‐dimensional shift correlated and j‐resolved NMR spectroscopy , 1991, Magnetic resonance in medicine.

[33]  D. Paty,et al.  Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown products , 1993, The Lancet.

[34]  J. Dawson,et al.  The Histology of Disseminated Sclerosis , 1916, Edinburgh Medical Journal.

[35]  R. Poston,et al.  Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis , 1989, Journal of the Neurological Sciences.

[36]  R E Lenkinski,et al.  MR proton spectroscopy in multiple sclerosis. , 1992, AJNR. American journal of neuroradiology.

[37]  H. Powell,et al.  Pathology of multiple sclerosis. , 1983, Neurologic clinics.

[38]  P M Matthews,et al.  Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.

[39]  G. Barker,et al.  Detection of myelin breakdown products by proton magnetic resonance spectroscopy , 1993, The Lancet.

[40]  J. Olesen,et al.  Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis , 1991, Magnetic resonance in medicine.